Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

VTGN

VistaGen Therapeutics Inc

Apr 15 • 04:00PM ET

4.75

Dollar change -0.14
Percentage change -2.86	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF PSIL AVSC IBRN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.51	Insider Own	10.12%	Shs Outstand	27.03M	Perf Week	-8.12%
Market Cap	128.39M	Forward P/E	-	EPS next Y	-1.96	Insider Trans	0.00%	Shs Float	24.29M	Perf Month	21.17%
Income	-32.07M	PEG	-	EPS next Q	-0.36	Inst Own	55.25%	Short Float	5.26%	Perf Quarter	-12.84%
Sales	1.04M	P/S	123.45	EPS this Y	81.23%	Inst Trans	-91.35%	Short Ratio	4.57	Perf Half Y	41.79%
Book/sh	4.56	P/B	1.04	EPS next Y	-22.54%	ROA	-39.89%	Short Interest	1.28M	Perf Year	13.58%
Cash/sh	4.68	P/C	1.01	EPS next 5Y	-	ROE	-44.55%	52W Range	1.62 - 24.71	Perf YTD	-7.59%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.01%	ROI	-25.65%	52W High	-80.78%	Beta	0.84
Dividend TTM	-	Quick Ratio	30.75	Sales past 5Y	-29.68%	Gross Margin	25.44%	52W Low	193.21%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	30.75	EPS Y/Y TTM	62.00%	Oper. Margin	-3252.53%	RSI (14)	47.39	Volatility	6.52% 7.40%
Employees	33	Debt/Eq	0.02	Sales Y/Y TTM	-133.77%	Profit Margin	-3076.62%	Recom	1.00	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	84.74%	Payout	-	Rel Volume	0.98	Prev Close	4.89
Sales Surprise	-43.33%	EPS Surprise	27.27%	Sales Q/Q	129.06%	Earnings	Feb 13 AMC	Avg Volume	279.46K	Price	4.75
SMA20	-0.67%	SMA50	-0.68%	SMA200	9.31%	Trades		Volume	274,505	Change	-2.86%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy	$15
Aug-07-23	Upgrade	Maxim Group	Hold → Buy	$30
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	Jefferies	Buy → Hold
May-20-21	Initiated	Robert W. Baird	Outperform	$9
Feb-18-21	Initiated	Jefferies	Buy	$6
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy	$6
Feb-08-18	Reiterated	Chardan Capital Markets	Buy	$30 → $22
Mar-28-17	Initiated	Maxim Group	Buy	$4

Show Previous Ratings

Apr-09-24 01:28PM	Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027 (InvestorPlace)
08:30AM	Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference (Business Wire)
Apr-01-24 08:30AM	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 (Business Wire)
Mar-31-24 10:00AM	Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027 (InvestorPlace)
Mar-26-24 06:24AM	30 Countries with the Lowest Depression Rates (Insider Monkey)
08:30AM	Loading…
Mar-11-24 08:30AM	Vistagen to Present at Stifel 2024 Virtual CNS Days (Business Wire)
Feb-28-24 08:30AM	Vistagen to Present at TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-21-24 09:55AM	Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect? (Zacks)
Feb-19-24 12:24PM	3 Revolutionary Biotech Stocks Poised for 10X Surge (InvestorPlace)
Feb-15-24 08:20AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript (Insider Monkey)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.00%
Feb-13-24 04:59PM	Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ... (GuruFocus.com)
04:20PM	Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update (Business Wire)
Feb-07-24 07:38AM	3 Penny Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Feb-06-24 08:30AM	Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 (Business Wire)
09:04AM	Loading…
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Dec-29-23 08:40AM	How Vistagen (VTGN) Stock Stands Out in a Strong Industry (Zacks)
Dec-27-23 08:30AM	Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -6.85%
Nov-11-23 01:03PM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:30PM	Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results (Business Wire) -6.17%
Nov-08-23 08:30AM	Vistagen to Present at Stifel 2023 Healthcare Conference (Business Wire) -11.37%
Nov-07-23 08:30AM	Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences (Business Wire)
Nov-06-23 08:00AM	Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023 (Business Wire)
Oct-05-23 08:30AM	Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (Business Wire) -9.18%
Oct-02-23 07:30AM	Vistagen Announces Pricing of $100 Million Underwritten Offering (Business Wire) -19.85%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-12-23 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (Business Wire)
Sep-05-23 09:00AM	Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagens Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan (Business Wire)
Aug-22-23 08:30AM	Vistagen Appoints Cindy Anderson as Chief Financial Officer (Business Wire) +7.68%
07:37AM	Loading…
Aug-15-23 07:37AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.77%
Aug-11-23 10:34AM	Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News (Zacks) -14.57%
Aug-10-23 04:21PM	Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results (Business Wire) +6.82%
10:31AM	COMMODORE CAPITAL LP Acquires New Stake in Vistagen Therapeutics Inc (GuruFocus.com)
03:49AM	AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (PR Newswire)
Aug-08-23 04:30PM	Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023 (Business Wire) -43.14%
Aug-07-23 05:46PM	Social anxiety nasal spray study results make Peninsula biotech's stock shoot up more than 600% (American City Business Journals) +676.79%
04:12PM	Biotech Firm Pops 677% on Social Anxiety Spray Trial Success (Bloomberg)
08:30AM	Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (Business Wire)
Jul-17-23 08:00AM	Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Sprays Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain (Business Wire)
Jul-13-23 04:05PM	Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinsons Disease (Business Wire)
Jun-28-23 04:25PM	Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results (Business Wire)
Jun-27-23 04:30PM	Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023 (Business Wire)
Jun-23-23 08:30AM	Vistagen Regains Full Compliance with Nasdaq Listing Requirements (Business Wire)
Jun-21-23 08:30AM	Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder (Business Wire) -7.22%
Jun-16-23 12:36PM	Revolutionizing mental health treatment: Vistagen Therapeutics' nasal spray solution (News Direct)
08:30AM	Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest (Business Wire)
Jun-13-23 08:00AM	Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine (Business Wire) -10.91%
Jun-07-23 09:00AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes (Business Wire) -9.21%
Jun-06-23 04:30PM	Vistagen to Present at Jefferies 2023 Global Healthcare Conference (Business Wire) -25.75%
09:25AM	Vistagen Announces Stockholder-Approved Reverse Stock Split (Business Wire)
Jun-01-23 08:30AM	Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Business Wire)
May-30-23 04:15PM	Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Business Wire)
May-24-23 08:30AM	Vistagen Awarded Mental Health Americas Platinum Bell Seal for Workplace Mental Health (Business Wire)
Apr-19-23 08:30AM	Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference (Business Wire)
Apr-06-23 08:30AM	Vistagen Receives New European Patent for AV-101 (Business Wire)
Mar-30-23 03:18PM	Social Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It (Benzinga)
08:30AM	FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder (Business Wire)
Mar-22-23 08:30AM	Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder (Business Wire) +16.37%
Mar-08-23 08:30AM	Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder (Business Wire)
Mar-02-23 08:30AM	Vistagen to Present at Cowen 43rd Annual Health Care Conference (Business Wire)
Mar-01-23 08:30AM	Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine (Business Wire)
Feb-08-23 12:49PM	VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial (Benzinga) -28.68%
Feb-07-23 06:15PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results (Business Wire)
Feb-06-23 09:09AM	Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023 (Business Wire) -16.83%
Feb-02-23 09:00AM	Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition (Business Wire) +8.91%
Jan-24-23 08:30AM	Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder (Business Wire)
Jan-19-23 08:30AM	Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023 (News Direct) -10.14%
Jan-10-23 08:30AM	Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety (Business Wire) +5.80%
Dec-30-22 08:30AM	Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder (Business Wire) +8.65%
Dec-21-22 10:56AM	Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition (Benzinga)
08:30AM	Vistagen to Acquire Pherin Pharmaceuticals (Business Wire)
Dec-16-22 08:35AM	KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire) +30.09%
Dec-13-22 08:35AM	KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th (GlobeNewswire)
Dec-06-22 08:30AM	Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder (Business Wire) +5.38%
Nov-30-22 08:30AM	Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder (Business Wire)
Nov-17-22 08:30AM	Vistagen Announces Publication in Cells Demonstrating AV-101s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease (Business Wire)
Nov-15-22 12:00PM	What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock (Zacks)
Nov-10-22 06:45PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +15.45%
04:30PM	Vistagen Reports Second Quarter Financial Results and Provides Corporate Update (Business Wire)
Nov-04-22 08:30AM	Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022 (Business Wire)
Nov-03-22 08:30AM	Vistagen to Present at Stifel 2022 Healthcare Conference (Business Wire)
Oct-26-22 09:00AM	Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ (Business Wire) +5.89%
Oct-22-22 08:02AM	Shareholders Will Likely Find VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) CEO Compensation Acceptable (Simply Wall St.)
Oct-19-22 04:30PM	Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022 (Business Wire)
Oct-06-22 08:30AM	Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote "FOR" Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary (Business Wire)
Oct-03-22 08:30AM	Vistagen to Participate at Cantor Neurology & Psychiatry Conference (Business Wire) +5.52%
Sep-24-22 08:10AM	Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m (Simply Wall St.)
Sep-20-22 08:30AM	Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit (Business Wire)
Sep-19-22 08:30AM	Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects (Business Wire) -5.18%
Sep-09-22 08:30AM	Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences (Business Wire) +5.84%
Sep-08-22 02:24PM	Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial (Benzinga) +18.36%
08:00AM	Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis (Business Wire)
Aug-11-22 04:20PM	VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update (Business Wire)
Aug-09-22 08:30AM	VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022 (Business Wire) -5.23%
Jul-22-22 09:06AM	VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study (Benzinga) -85.99%
08:00AM	VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B (Business Wire)
Jul-20-22 10:42AM	2 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +14.89%
Jul-12-22 08:30AM	VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit (Business Wire) -6.12%

VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COMMODORE CAPITAL LP	10% Owner	Aug 07 '23	Buy	23.15	775,756	17,961,079	1,575,000	Aug 09 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTGN

VistaGen Therapeutics Inc

Upgrade your FINVIZ experience